英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
exclusa查看　exclusa　在百度字典中的解释百度英翻中〔查看〕
exclusa查看　exclusa　在Google字典中的解释Google英翻中〔查看〕
exclusa查看　exclusa　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . .
    Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
  • Esperion Announces New Data from CLEAR Outcomes Highlighting . . .
    The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • Statin alternative lowers heart-related deaths - Harvard Health
    The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
  • NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • Esperion’s Bempedoic Acid Receives Multiple Class 1 . . .
    In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture
  • Lower LDL Is Better In New ACC AHA Guidelines, Making The . . .
    Key Takeaways New LDL cholesterol treatment guidelines from the ACC, AHA and peer organizations recommend earlier screening and treatment, including adding Amgen’s and Regeneron Sanofi’s PCSK9 inhibitors and Esperion’s Nexletol (bempedoic acid) and Nexlizet to statins
  • Esperions Cholesterol Drug Bempedoic Acid Added To Major US . . .
    Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardiology (ACC) American Heart Association (AHA) Multisociety Guideline on the Management of Dyslipidemia "The reintroduction of guideline-directed LDL-C targets to reduce cumulative LDL-C exposure emphasizes the importance of earlier
  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
    CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid (Nexletol) modestly reduced the risk of a 4-component composite of major adverse cardiovascular events (MACE) compared to placebo





中文字典-英文字典  2005-2009